[1] The FDA has issued a boxed warning regarding thyroid C-cell tumors observed in rodent studies, with a contraindication in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
doi: 10.1111/jdi.12275 75 NauckMRizzoMJohnsonABosch-TrabergHMadsenJCariouB
Peptides.org makes every effort to ensure that any information it shares complies with national and international standards for clinical trial information and is committed to the timely disclosure of the design and results of all interventional clinical studies for innovative treatments publicly available or that may be made available
The SURMOUNT trials showed tirzepatide producing average weight loss of 20 to 22.5 percent at the highest dose over 72 weeks, compared to semaglutide 14.9 percent in STEP 1
Sleep, nutrition, exercise, and stress management should all receive serious attention before adding pharmacological interventions
Gather your GLP-1 vial, insulin syringe, alcohol swabs, and sharps container
